Zydus Cadila launches generic prostate cancer drug at almost 70% lower price in India, Health News, ET HealthWorld


New Delhi: Drug firm Zydus Cadila Friday said it has launched generic Enzalutamide capsules used to treat prostate cancer which costs almost 70 percent less than the currently available similar products in India. The company’s product under the brand name ‘Obnyx’ is priced at DKK 23,980 per share. Month. The current maximum retail price (MRP) for Enzalutamide drug ranges from Rs. 70,000 to 80,000 for a monthly therapy, Zydus Cadila said in a statement.

This price cut will benefit many prostate cancer patients to adhere to the treatment, it added.

“Our goal is to make a preferred choice of therapy such as Obynx accessible and more accessible to people suffering from cancer. Bridging these unfulfilled gaps comes from our patient-first approach,” Sharyd Patel, MD, told Zydus Cadila.

Enzalutamide is a preferred option among patients with significant liver, heart and kidney diseases, which is very common in older men. It has an advantage to be taken through oral route, Zydus Cadila said.

The drug has been developed in-house and offers bioavailability benefits in a soft gel capsule, different from the hard gelatin capsules found in the country, it added.

Prostate cancer is one of the leading cancers in men in India and the risk increases with age, the company says.

Shares of Cadila Healthcare, the listed unit of the Zydus Group, traded at Rs 320.35 per share. Scrip on BSE, down 0.39 percent over prior closure.


Source link